We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Management of immunosuppression in post‐transplant lymphoproliferative disorders treated with CAR T cells.
- Authors
Jimkap, Nathacha; El Baroudi, Oussama; Lemoine, Jean; Pievani, Daniele; Pastoret, Cédric; Houot, Roch
- Abstract
This document provides a summary of a literature analysis on the use of CAR-T therapy for post-transplant lymphoproliferative disorder (PTLD). The analysis found that CAR-T therapy was effective in treating PTLD, with an overall response rate of 67.3% and a complete remission rate of 59.2%. The most common side effects were cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS). The management of immunosuppressive therapy (IS) during CAR-T therapy remains a challenge, with no consensus on the optimal approach. The analysis suggests that IS should be suspended for as long as possible to maximize the duration of response. Close monitoring of immune reconstitution and graft rejection is crucial for tailoring IS in a personalized manner.
- Subjects
LYMPHOPROLIFERATIVE disorders; T cells; HEMATOPOIETIC stem cell transplantation
- Publication
British Journal of Haematology, 2024, Vol 204, Issue 5, p2112
- ISSN
0007-1048
- Publication type
Article
- DOI
10.1111/bjh.19355